BillionToOneBLLN +2.04%13 Forward PE Ratio is 124.42 as of Jul. 01, 2026. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 87 Medical Diagnostics & Research companies, BillionToOne ranks worse than 95.4% on this metric.
BillionToOne's Forward PE Ratio for today is 124.42.
BillionToOne (NAS:BLLN) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
BillionToOne Forward PE Ratio Related Terms
BillionToOne Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for BillionToOne's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BillionToOne Forward PE Ratio Chart
BillionToOne Annual Data
Trend
2025-12
Forward PE Ratio
304.78
BillionToOne Quarterly Data
2025-12
2026-03
Forward PE Ratio
304.78
155.25
BLLN vs SHC, VCYT, RDNT: Forward PE Ratio Comparison
For the Diagnostics & Research subindustry, BillionToOne's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BillionToOne Forward PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BillionToOne's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where BillionToOne's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
BillionToOne (BLLN) has a Forward PE Ratio of 124.42 as of Jul. 01, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on BillionToOne and its competitors. According to the industry distribution chart, BillionToOne ranks #83 out of 87 companies in the Medical Diagnostics & Research industry, placing it in the top 95.4%.
Is BillionToOne's Forward PE Ratio too high?
BillionToOne's current Forward PE Ratio is 124.42. The Medical Diagnostics & Research industry median Forward PE Ratio is 21.92. BillionToOne's value of 124.42 is 467.6% above this industry median. Based on the distribution chart, BillionToOne ranks #83 out of 87 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's Forward PE Ratio compare to SHC and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, BillionToOne ranks #83 out of 87 companies for Forward PE Ratio. This places BillionToOne in the lower half of its industry. The industry median Forward PE Ratio is 21.92. BillionToOne's value of 124.42 is 467.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Diagnostics & Research company?
The median Forward PE Ratio among Medical Diagnostics & Research companies is 21.92, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BillionToOne's current Forward PE Ratio of 124.42 is 467.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on BillionToOne and its competitors. For the Medical Diagnostics & Research industry, the median Forward PE Ratio is 21.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BillionToOne's current Forward PE Ratio is 124.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current Forward PE Ratio of 124.42. The current Forward PE Ratio is 124.42 and 467.6% above the Medical Diagnostics & Research industry median of 21.92. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For BillionToOne (BLLN), the current Forward PE Ratio is 124.42 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score
Get the complete analysis for BLLN
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLLN has been successfully added to your 